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Actin nucleation by WH2 domains
at the autophagosome
Amanda S. Coutts1 & Nicholas B. La Thangue1
Autophagy is a catabolic process whereby cytosolic components and organelles are degraded
to recycle key cellular materials. It is a constitutive process required for proper tissue
homoeostasis but can be rapidly regulated by a variety of stimuli (for example, nutrient
starvation and chemotherapeutic agents). JMY is a DNA damage-responsive p53 cofactor
and actin nucleator important for cell survival and motility. Here we show that JMY regulates
autophagy through its actin nucleation activity. JMYcontains an LC3-interacting region, which
is necessary to target JMY to the autophagosome where it enhances the autophagy
maturation process. In autophagosomes, the integrity of the WH2 domains allows JMY to
promote actin nucleation, which is required for efﬁcient autophagosome formation. Thus our
results establish a direct role for actin nucleation mediated by WH2 domain proteins that
reside at the autophagosome.
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M
acroautophagy (referred to as autophagy) is a catabolic
process important for cell survival and numerous
environmental cues can stimulate autophagy, which is
maintained at basal levels to ensure cellular homoeostasis1–3.
Nutrient deprivation is the most well-studied effector of
autophagy, but other types of stress, such as those induced by
drugs and chemotherapeutic agents, can trigger autophagy1,4.
Although autophagy can provide a means of tumour cell growth
and survival, in some cases it may also be an effective cell death
inducer1,4. When autophagy is initiated, a crescent-shaped double
membrane, the isolation membrane or phagophore, is formed
that eventually closes in on itself to form the autophagosome
around cellular macromolecules, which can include damaged or
unwanted organelles or proteins, lipids and nucleic acids5,6.
At later stages of autophagy, the autophagosomes may fuse with
endocytic vesicles before ultimately fusing with the lysosome
resulting in the degradation of cellular material6,7. In the initial
stages of autophagy, the autophagic proteins are recruited to a
membrane to initiate membrane nucleation from a variety of
sources including the endoplasmic reticulum, golgi, mitochondria
and recycling endosomes8.
While studies have identiﬁed a large number of Atg
(autophagy-related) proteins whose step-wise roles in the
autophagy process are becoming clearer, the mechanical
processes and proteins (especially non-Atg) involved in regulating
the induction, expansion and fusion of the autophagosome are
incompletely understood6. Although research has demonstrated
the involvement of the cytoskeleton, especially the microtubule
system, in various aspects of autophagy the role of the actin
cytoskeleton in autophagy is unclear2. It is interesting to note that
while a majority of actin polymerization occurs at the
membrane–cytosol interface9, in mammalian cells very little is
known about the role of actin in autophagy.
JMY was initially described as a cofactor that can inﬂuence p53
activity during the DNA damage response10,11. Since then, JMY
has been shown to be a WH2 domain-containing actin nucleator
that can shuttle between the nucleus and the cytoplasm,
dependent on stress12,13. Importantly, JMY is unusual in
that it can nucleate actin in both an Arp2/3-dependent and
-independent fashion, suggesting a highly specialised role13.
Here we report that JMY plays a role in cells undergoing
autophagy. Signiﬁcantly, we found that JMY is recruited to
LC3-containing autophagosomes when cells are exposed to a
variety of autophagy-inducing agents, including starvation and
drug treatment. This requires the amino (N)-terminal region of
JMY, which contains an LC3-interacting region (LIR), required
for JMY to localize at the autophagosome where it enhances
autophagosome formation and maturation. Most interestingly,
the LIR in JMY is also required for actin nucleation activity,
which is necessary for autophagosome formation and maturation.
Depletion of JMY leads to markedly decreased cell survival in
autophagocytic cells, while JMY overexpression enhances cell
survival, dependent on the presence of its actin-nucleating activity
and ability to enhance autophagosome formation. Our results
establish for the ﬁrst time actin nucleation at the autophagosome
and suggest a mechanistic role for actin in autophagosome
formation and maturation.
Results
JMY localizes to the autophagosome. As nuclear JMY is
responsive to a variety of cellular stressors such as UV and
hypoxia10,12,14, and is resident in the cytoplasm where it can
inﬂuence actin nucleation, we were interested in examining
whether JMY takes on a more general role in cellular stress, such
as autophagy. In cells treated with a variety of agents that
effectively induce autophagy (notably stress induced by drug
treatment and nutrient starvation), a proportion of JMY localized
to distinct cytoplasmic foci reminiscent of autophagosomes
(Supplementary Fig. 1a). During the autophagic process the
ATG8 homologue, MAP1LC3 (referred to as LC3), becomes
lipidated and cleaved (LC3-II) and is incorporated onto the
double-membrane phagophore that is destined to become the
autophagosome5. Assessing LC3-II either by immunoblotting or
visualization of LC3 puncta is the most widely accepted method
of determining autophagy levels15. A signiﬁcant proportion of
JMY also colocalized with LC3-containing autophagosomes
(Fig. 1a and Supplementary Fig. 1b), indicating that JMY can
accumulate at autophagosomes during autophagy induction.
Inhibiting autophagic ﬂux can be accomplished by preventing
turnover of LC3-II containing autophagosomes using either
tubastatin A or baﬁlomycin A1 (refs 16,17). These treatments
resulted in the accumulation of LC3 foci and colocalization of
JMY with LC3 (Supplementary Fig. 1b). Autophagy targets
macromolecules for degradation but JMY levels were not
consistently downregulated during autophagy (Supplementary
Fig. 1c,d). The autophagy cargo protein p62 (sequestosome
1/SQSTM1) interacts with LC3 via an LIR and is known to be
degraded during autophagy18 and, as expected, its levels
are consistently upregulated during baﬁlomycin A1 (a late
phase autophagy inhibitor19) treatment in contrast to JMY
(Supplementary Fig. 1e).
JMY contains an LIR. To identify the region involved in
targeting JMY to the autophagosome, we expressed JMY
derivatives (Fig. 1b) in drug-treated (SAHA) U2OS cells to
induce autophagy. Previously, JMY was shown to be capable of
inducing actin-containing structures in cells, via its WH2
domain-containing VCA region12,13 (Fig. 1b). The C-terminal
region containing the WH2 domains was dispensable for the
localization of JMY at the autophagosome (Fig. 1c and
Supplementary Fig. 2a). Surprisingly, removal of the N-terminal
region of JMY (Fig. 1b) completely ablated the ability of JMY
to colocalize with LC3 at the autophagosome (Fig. 1c and
Supplementary Fig. 2a). Closer examination of this region
revealed a sequence with similarity to an LIR (Fig. 1b). In
general, the LIR confers on proteins the ability to interact with
members of the LC3 family and target to the phagophore, and is
present in proteins recruited as components of the autophagy
machinery, including ATG1 (ULK1/2), ATG13 and ATG4
(Fig. 1b)20. The LIR sequence resembles the consensus W/F/
YxxL/I/V (Fig. 1b), frequently in the presence of surrounding
acidic residues with a serine (S) or threonine (T)21. Of note, JMY
has a number of acidic residues ﬂanking the motif as well as an
adjacent S residue (Fig. 1b). The JMY LIR is highly conserved
across species, arguing for its importance in JMY function
(Fig. 1b). Mutating the critical tryptophan (W) and valine (V) to
an alanine (A) in JMY (mtLIR, Fig. 1b) resulted in a complete loss
of autophagosome localization (Fig. 1c and Supplementary
Fig. 2b). Indeed, rather than localizing to autophagosomes,
mtLIR remained evenly distributed throughout the cell (Fig. 1c
and Supplementary Fig. 2b). Moreover, JMY and LC3 interact in
cells as LC3 co-immunoprecipitated with JMY (Fig. 1d and
Supplementary Fig. 2c). Importantly, JMY could interact directly
with LC3B (Fig. 1e), which was mediated by the N-terminal half
of JMY (Supplementary Fig. 2d). Further, the interaction between
the N-terminal region of JMY and LC3 was dependent on the
presence of an intact LIR (Supplementary Fig. 2e). To provide
further evidence that the LIR in JMY is a functional LIR, we
swapped the LIR in p62 with the LIR in JMY (Supplementary
Fig. 2f), which maintained the localization of p62 at the
autophagosome during both SAHA and starvation-induced
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autophagy (Supplementary Fig. 2f). Thus, JMY contains a
functional LIR required for targeting its activity to the
autophagosome.
JMY inﬂuences autophagosome formation. We next explored
the possibility that JMY inﬂuences autophagosome formation and
might thus be involved in the maturation process. Time-course
studies demonstrated that depletion of JMY resulted in a marked
reduction in LC3-II levels during drug-induced autophagy
(Fig. 2a and Supplementary Fig. 3a,b). This was unlikely to be an
off-target effect as three individual small interfering RNAs
(siRNAs) targeting JMY resulted in a similar decrease in LC3-II
levels (Supplementary Fig. 3c). Similar results were also seen
during starvation-induced autophagy (Fig. 2b and Supplementary
Fig. 3d,e). Of note, JMY depletion was able to signiﬁcantly impede
the formation of LC3-II during short time periods
of stress treatment (Fig. 2a,b and Supplementary Fig. 3a–e),
suggesting that JMY acts at an early stage in autophagosome
formation. We next examined the effect of JMY depletion on the
number of autophagosomes in individual cells by immuno-
ﬂuorescence, where we observed a signiﬁcant decrease in the
number of autophagosomes per cell during drug-induced
autophagy (Fig. 2c). This reduction in autophagosome number
was also reﬂected in reduced total autophagosome area per cell
(Fig. 2d). Interestingly, we also observed a reduction in the mean
autophagosome area in JMY-depleted cells (Fig. 2e), suggesting
that JMY inﬂuences autophagosome maturation.
As a decrease in LC3-II levels could be due to decreased
formation or increased turnover, we used baﬁlomycin A1
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Figure 1 | JMY localizes to autophagosomes through an LIR. (a) U2OS cells expressing HA-JMYwere treated with SAHA or starved with Earle’s balanced
salt solution (EBSS) for 6 h. Top panel: HA-JMY was detected with mouse anti-HA and LC3 with rabbit anti-LC3. Middle panel: rabbit anti-HA and mouse
anti-LC3 were used. Inset shows enlarged region as denoted. Scale bar, 10mm. (b) Schematic of JMY illustrating the position of the WH2 domains and the
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comparing the JMY LIR region to that of other known LIR-containing proteins. Sequences of some known LIR-containing proteins compared with JMY,
adapted from ref. 45. Amino-acid residue position is given. Lower right: The JMY LIR is highly conserved across species. Blue highlighted residues show
conservation of core sequence (W/V) and potential phosphorylation site (S). h, human; m, mouse; c, canine; z, zebraﬁsh; x, xenopus; At, Arabidopsis.
(c) JMY and its derivatives were expressed in U2OS cells and treated with SAHA 6h. JMY was detected with anti-HA antibody and rabbit anti-LC3 was
used to detect endogenous LC3. Scale bar, 10mm. (d) MCF7 cells were treated with SAHA before collecting for immunoprecipitation (IP) with anti-JMY
antibody (JMY) or non-speciﬁc IgG control (ns). Inputs (In) represent 2% of extract. (e) His-JMY was incubated with GST-LC3B or GST and complexes
isolated using glutathione sepharose 4B. Inputs represent total protein loading. n¼ 3 independent experiments. (f) Table summarising properties of JMY
derivatives. þ þ ¼ strong,þ ¼moderate,  ¼ no/weak.
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(which inhibits the late phase of autophagy by preventing fusion
with the lysosomes19) to uncouple these processes. Notably, JMY
depletion did not prevent autophagic ﬂux, as treatment with
baﬁlomycin A1 was able to enhance LC3-II levels even in the
presence of JMY siRNA treatment, but JMY-depleted cells still
demonstrated lower LC3-II levels (Fig. 2f and Supplementary
Fig. 3f), consistent with a defective autophagy process. In
addition, autophagy involves fusion of the phagosome with the
lysosome15, but we were unable to observe any signiﬁcant
colocalization of JMY with lysosomal markers (cathepsin D and
0
5
10
15
20
25
30
35
40
JMY
Actin
LC3
Au
to
ph
ag
os
om
es
 p
er
 c
el
l
Fo
ld
 L
C3
II 
lev
e
ls
0
0.2
0.4
0.6
0.8
1
1.2
1.4
*
I
II 15
150
100
50
JMY
Actin
LC3
0
0.5
1
1.5
2.5
2
Fo
ld
 L
C3
II 
lev
e
ls
I
II 15
150
100
50
Si: NT JMY Si: NT JMY
Si: NT JMY
– 2 4 6 24 – 2 4 6 24 :h SAHA :h EBSS0.5 1 2 4 0.5 1 2 4
a b c
1.44
1.46
1.48
1.5
1.52
1.54
1.56
1.58
1.6
1.62
1.64
JMY
Actin
LC3
p62
Au
to
ph
ag
os
om
e 
m
ea
n 
ar
ea
Au
to
ph
ag
os
om
e
 
 
to
ta
l a
re
a/
ce
ll
* *
10
0
20
30
40
50
60
70
Fo
ld
 L
C3
II 
lev
e
ls
I
II 15
150
100
50
60
Si: NT JMY Si: NT JMY
Si: NT JMY
:h SAHA
70
60
50
40
30
20
10
0
– + – + – + – +
Baf Baf
d e f
JMY
Actin
LC3
10
0
20
30
40
50
60
Fo
ld
 L
C3
II 
lev
e
ls
I
II 15
40
150
100
:h SAHA– + – + – +
g
JMY
Actin
LC3
Baf BafBaf
0
10
20
30
40
50
60
70
80
90
Fo
ld
 L
C3
II 
lev
e
ls
I
II
15
40
150
100
Vec JMY mtLIRVec JMY mtLIR h
– – –+ + + – – –+ + + : SAHA
Figure 2 | JMY inﬂuences autophagosome formation. (a) U2OS cells were treated with non-targeting (NT) or JMY siRNA for 72 h before treating with
SAHA for the indicated time points. Actin was used as a loading control. n¼ 8 independent experiments. The graph below shows fold LC3-II levels after
normalizing for actin. (b) U2OS cells were treated with NT or JMY siRNA for 72 h before replacing the medium with EBSS for the indicated time points.
n¼ 5 independent experiments. The graph below shows fold LC3-II levels after normalizing for actin. (c) Quantitation of autophagosome number in U2OS
cells treated with NTor JMYsiRNA for 72 h. Cells were treated with SAHA for 6 h before ﬁxation and processing for immunoﬂuorescence. Graph represents
the number of autophagosomes/cell calculated using an IN Cell Analyser 1000. The data represent n¼ 3 independent experiments with43,000 cells per
treatment. *Po0.02, Student’s t-test. (d) Quantitation of total autophagosome area/cell from cells treated as in c. *Po0.005, Student’s t-test.
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for actin. Error bars in all graphs are mean±s.e.m.
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LAMP2; Supplementary Fig. 3g,h), further supporting the notion
that JMY is involved in a stage of autophagy that is prior to
lysosomal fusion.
We created stable cell lines with wild-type JMY and the mtLIR
derivative to explore the role of the LIR motif in the ability
of JMY to inﬂuence autophagosome development. Wild-type
JMY-expressing cells had an increased level of LC3-II compared
with control cells (Fig. 2g and Supplementary Fig. 2g,h),
supporting the earlier conclusion that JMY has a role in
autophagosome formation. Interestingly, cells stably expressing
mtLIR demonstrated consistently reduced levels of LC3-II
when compared with wild-type-expressing cells (Fig. 2g and
Supplementary Fig. 2g,h). Indeed, in mtLIR expressing
cells LC3-II levels often appeared reduced compared with
their control-treated counterparts (Fig. 2g and Supplementary
Fig. 2g,h), yet were able to undergo autophagic ﬂux (as assessed
using baﬁlomycin A1 treatment; Fig. 2h). Overall, these results
indicate that JMY is involved in autophagosome formation and
highlight the importance of the LIR motif in this role.
Actin nucleation is involved in autophagosome formation.
Interestingly, the N-terminal region of JMY is required for its
ability to form cytoplasmic actin-containing structures, despite
the presence of the WH2 domains (Fig. 1f and Supplementary
Fig. 4a). More surprisingly, mutation of the LIR alone was
sufﬁcient to prevent the formation of the majority of cytoplasmic
actin structures by JMY (Supplementary Fig. 4a), even though we
were still able to observe colocalization of JMY and actin at the
leading edge (Supplementary Fig. 4a), where previously it has
been shown to localize to inﬂuence cell motility12,13. This
suggested to us a potential link between actin nucleation and
autophagosome formation. Therefore, we tested whether JMY
was able to induce actin-containing structures during autophagy,
and examined the colocalization of JMY and actin under
conditions of autophagy. Notably, we observed signiﬁcant
colocalization of JMY with cytoplasmic actin structures, but not
with mtLIR (Supplementary Fig. 4b,c).
Since the ability of JMY to induce actin-containing cytoplasmic
structures requires not just the WH2 domains but also an intact
LIR (Fig. 1f), we reasoned that actin may be involved in
autophagosome development during which JMY takes on a
mechanical role. This idea was compatible with the fact that JMY
expression induced elongated autophagosomes, reminiscent of
cytoplasmic JMY-induced actin-containing structures observed in
normal conditions (compare inset Supplementary Fig. 4a with
Supplementary Fig. 4d). As JMY can incorporate globular
(G)-actin into actin-containing structures in cells12,13, we
performed in situ actin incorporation assays under conditions
when JMY is present at autophagosomes. Indeed, incorporation
of actin at the sites of JMY localization was apparent
(Supplementary Fig. 4e). Signiﬁcantly, during both drug
treatment and starvation-induced autophagy, we observed
colocalisation of actin with LC3 at autophagosomes (Fig. 3a).
Occasionally these structures had an elongated ﬁlamentous
structure similar to those observed with JMY (Fig. 3a top panel,
enlarged inset). Moreover treatment with baﬁlomycin A1 resulted
in some cells displaying a striking colocalization of LC3 with
actin-containing foci (Fig. 3a lower panel). Most importantly, we
observed colocalization of JMY and actin with LC3 at
autophagosomes (Fig. 3b), and further the presence of JMY
enhanced the localization of actin at the autophagosome
(Fig. 3c,d), arguing that JMY is rate-limiting for the presence of
actin at autophagosomes.
Although the ability of JMY to localize at autophagosomes does
not require its WH2 domains (Fig. 1c and Supplementary
Fig. 2a), we reasoned that JMY may inﬂuence autophagosome
formation through its actin-nucleating activity, which is targeted
to the autophagosome dependent on an intact LIR (Fig. 1c and
Supplementary Fig. 4a–c). To explore this possibility we fused the
WH2 domain region of JMY to the N-terminus of LC3 in the
context of mcherry–GFP–LC3 (Supplementary Fig. 5a; ref. 22),
where JMY would not interfere with lipidation and membrane
association of LC3 which occurs at the C terminus23. The
addition of the WH2 domain region of JMY enhanced the level of
actin colocalization with the autophagosomes when compared
with mcherry–GFP–LC3 (Fig. 3e,f and Supplementary Fig. 5b,c).
We also often observed markedly elongated autophagosomes in
mcherry-GFP-WH2-LC3-expressing cells which colocalized with
actin (Fig. 3e), again arguing that JMY-dependent actin
nucleation at the autophagosome inﬂuences autophagosome
formation. We noted that autophagosomes formed in the
presence of JMYDWH2 were frequently enlarged and globular
(Supplementary Fig. 5d), which was reﬂected in an increased
mean area of the autophagosomes (Fig. 3g). Moreover, the
autophagosomes in JMYDWH2 cells often retained a prominent
perinuclear location (Supplementary Fig. 5d). Together these
observations suggest that aberrant development of the
autophagosome occurs in the absence of actin nucleation.
JMY can nucleate actin in both an Arp2/3-dependent and
-independent fashion 12,13 and mutation of a tryptophan
(W981A) residue in the WH2 domain region prevents Arp2/3-
dependent actin nucleation13. Although loss of Arp2/3-dependent
actin nucleation did not alter the ability of JMY to locate to
autophagosomes (Fig. 4a) it compromised, rather than abolished,
the ability to colocalize with actin during autophagy (Fig. 4a
compare middle and lower panels). This suggested that Arp2/3-
dependent actin nucleation plays a role in autophagosome
formation. To explore this idea further, we treated cells with
the Arp2/3 inhibitors CK-666 and CK-869 (ref. 24) during
autophagy which resulted in a reduction in LC3-II levels and
the number of autophagosomes, suggesting a dependency on
Arp2/3 activity for autophagosome formation (Fig. 4b,c and
Supplementary Fig. 6a–c). Further, using a panel of JMY stable
cell lines we compared the effects of actin nucleation on LC3-II
levels during autophagy. While loss of Arp2/3-dependent actin
nucleation in W981A rendered JMY less effective at inducing
autophagy compared with wild-type JMY, it was not completely
compromised (Fig. 4d). On the other hand, removal of the entire
WH2 domain resulted in a more dramatic reduction in LC3-II
(Fig. 4d). Together these observations suggest that JMY
is able to inﬂuence autophagosome formation in both an
Arp2/3-dependent and -independent fashion by having a
mechanical role dependent on actin nucleation.
JMY impacts on cell survival during autophagy. Autophagy can
both promote and inhibit the growth of cancer cells1. As drug
treatment, for example, the HDAC inhibitor SAHA, is a potent
inducer of apoptosis as well as autophagy25, we depleted JMY
from cells treated with SAHA and performed FACS analysis to
examine the effects. Interestingly, JMY depletion resulted in a
signiﬁcant enhancement of apoptosis (Fig. 4e). We also observed
similar effects on apoptosis driven by mTOR inhibition
(Supplementary Fig. 6d), suggesting that JMY acts as a
pro-survival factor by facilitating autophagy. Moreover, under
starvation conditions JMY was able to augment viability
(Supplementary Fig. 6e,f).
Numerous studies have implied a role for p53 in autophagy
regulation26–28 and, previously, we have shown that JMY is a p53
cofactor capable of inﬂuencing p53-dependent cell survival10–12.
To explore the possibility of a transcriptional role of JMY in LC3
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regulation, we examined LC3 mRNA levels in JMY-depleted cells
at time points during autophagy where JMY inﬂuences L3C-II
levels. JMY depletion caused a modest decrease in LC3 mRNA
levels under starvation (Supplementary Fig. 7b), but not following
6 h SAHA treatment (Supplementary Fig. 7a). To further
ascertain if the effects of JMY could be mediated in part by its
nuclear role as a p53 cofactor, we depleted JMY in matched
p53þ /þ and p53 / HCT116 cells. Regardless of the presence
or absence of p53, JMY depletion still resulted in a decrease in
LC3-II levels (Supplementary Fig. 7c), moreover, JMY-induced
PARP cleavage was not dependent on p53 (Supplementary
Fig. 7c). Thus, the inﬂuence of JMY on cell survival during
autophagy is mediated primarily through a cytoplasmic role of
JMY independent of p53 activity. Indeed, the ability of JMY to
inﬂuence cell survival correlated with actin nucleation
activity and modulation of LC3 levels, as JMYDWH2 cells
exhibited higher levels of apoptosis compared to wild-type JMY
expressing cells (Fig. 4f). Together these results suggest
that JMY, through its inﬂuence on autophagosome formation
in an actin-mediated fashion, is able to inﬂuence cell viability
(Fig. 4g).
Discussion
Autophagy is highly relevant for numerous diseases including
cancer, lysosomal storage diseases, neurodegenerative diseases as
well as processes such as aging, development and immunity29.
Our study has demonstrated a novel role for JMY in autophagy,
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antibody and false coloured red for visualization purposes. Scale bar, 10mm. (f) Quantitative data of cells treated in e. Data are represented as the Pearson’s
coefﬁcient of the LC3 and actin signal correlation. n¼420 cells per treatment, two independent experiments. *Po0.001, Student’s t-test. (g) The mean
area of the autophagosomes quantiﬁed in 6 h SAHA treated HA-JMYand HA-JMYDWH2 expressing U2OS cells using an IN Cell Analyser 1000, n¼4150
cells per treatment, two independent experiments. *Po0.1, Student’s t-test. Error bars in all graphs are mean±s.e.m.
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where it acts to promote autophagosome formation through a
functional LIR motif. In a similar fashion to JMY, other LIR
motif-containing proteins contribute to various stages of
autophagosome formation and maturation21. However, the role
of JMY in autophagy appears novel and attributable to its ability
to nucleate actin. Thus, JMY augments the level of actin present
in the autophagosome, and the integrity of its WH2 domain
region coincides with efﬁcient autophagosome formation. The
fact that the autophagosomes formed in the presence of a JMY
derivative lacking actin-nucleating activity are often enlarged
suggests defects in autophagosome processing and maturation,
likely dependent on actin nucleation. Of interest, the JMYmtLIR
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Figure 4 | JMY inﬂuences survival during autophagy. (a) U2OS cells expressing HA-JMYand derivatives were treated with SAHA for 6 h before ﬁxation.
Scale bar, 10mm. (b) U2OS cells were treated with control (NT) or JMY siRNA for 72 h. Six hours before collecting cells were treated with SAHA with or
without the Arp2/3 inhibitor (CK-666; 20mM) as denoted before collecting. The graph below shows fold LC3-II levels after normalizing for actin.
(c) Quantitation of autophagosome number from cells treated with SAHA with or without CK-666 for 6 h. Graph represents n¼ 3 independent experiments
with41,200 cells per treatment. *Po0.02, Student’s t-test. (d) U2OS cells stably expressing HA-JMYand derivatives were treated with or without SAHA
for 6 h before collecting. The graph below shows fold LC3-II levels after normalizing for actin. (e) U2OS cells were treated with control (NT) or JMYsiRNA
for 72 h. The cells were treated with vehicle control ( ) or SAHA for 24 h before collecting and analysed by FACS. Graph represents percentage sub-G1 of
a representative experiment. n¼4 independent experiments, *Po0.02, Student’s t-test. Blots underneath represent input protein levels. (f) U2OS cells
stably expressing HA-JMY and derivatives were treated with SAHA for 24 h before collecting and analysed by FACS. Graph represents percentage sub-G1
of a representative experiment. n¼ 3 independent experiments, *Po0.05 Student’s t-test. (g) Model depicts the cytoplasmic role of JMY in inﬂuencing
autophagosome formation through its actin nucleation activity. Under normal conditions cytoplasmic JMY is able to induce the formation of new actin
ﬁlaments to facilitate cell motility and invasion. During conditions of stress leading to autophagy induction JMY is localized at the autophagosome where it
fosters autophagosome formation via its actin-nucleating activity, leading ultimately to enhanced cell survival. Actin is depicted by both red lines (leading
edge) and purple circles (autophagosome) to reﬂect differences in localization rather than chemical or structural composition. All error bars are
mean±s.e.m.
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lacks most cytoplasmic actin colocalization suggesting that a
functional LIR is required to allow actin nucleation via the WH2
domains in the C-terminal region. This would be consistent with
a mode of regulating JMY’s activity via allosteric mechanisms and
autoinhibition, similar to other WH2 domain-containing proteins
such as WASP30. Moreover, the fact that JMYmtLIR is still able to
colocalize with cortical actin ﬁlaments suggests that there is a
separation of JMY’s ability to nucleate actin to inﬂuence
autophagosome formation and that involved in directing cell
motility events.
JMY belongs to a family of type I actin nucleation-promoting
factors, which include WHAMM, WASH and WASP31. These
nucleation-promoting factors have a common C-terminal region
that contains the WH2 domain-containing VCA region and a
poly-proline-rich region but diverge at their N-terminus31,32.
WHAMM that shares the highest degree of identity to JMY has
been shown to be involved in endoplasmic reticulum to Golgi
transport33, while mammalian WASH localizes to early and
recycling endosomes34,35. WASH has been shown to be a negative
regulator of autophagy, although the inﬂuence of its actin-
nucleating activity on this ability is unknown36,37. It is likely that
JMY and other actin-nucleating proteins have distinct cellular
roles based on their localization to a particular organelle and in
this regard the divergent N-terminal region may provide
speciﬁcity, as well as control, over actin-nucleating activity. The
fact that JMY’s expression appears to be restricted to higher
eukaryotes38,39 suggests that it may function in a more specialized
form of autophagy required in higher organisms. This would
allow JMY to function speciﬁcally at the autophagosome where
the N-terminal region is required not only for targeting but also
activation of the actin-nucleating activity in the C-terminus.
Previous work has hinted at a role for actin in autophagsome
formation in mammalian cells, although the underlying
mechanism is unknown17,40 and our data support a role for
actin nucleation provided by JMY in this process.
JMY is thus a multifunctional protein that combines its
actin-nucleating activity with a functional LIR to nucleate actin
and foster autophagosome maturation and thereby impact on cell
survival (Fig. 4g). In particular JMY’s ability to inﬂuence the
outcome of cellular stress may be two-fold; in the cytoplasm it
can act to promote autophagy leading to survival, while in the
nucleus JMY can enhance p53-dependent apoptosis10,12.
Autophagy is highly relevant for numerous diseases including
cancer, lysosomal storage diseases, neurodegenerative diseases, as
well as processes such as aging, development and immunity29.
Our study provides a link between actin nucleation and
autophagy with cell survival during stress. This, in turn, may
also provide novel opportunities to modulate autophagosome
levels that will have a signiﬁcant impact on cell survival.
Methods
Plasmids, antibodies and reagents. The following plasmids have been previously
described; pcDNA3 HA-JMY, JMYDN, DWH2, pET28a JMY11,12. HA-p62 was a
gift from Qing Zhong41 (Addgene plasmid #28027). JMYmtLIR and p62/JMY LIR
were generated using the Stratagene QuickChange Site-directed mutagenesis kit.
mCherry–GFP–LC3 was a generous gift from Terje Johansen, University of
Tromso, Norway22. mcherry-GFP-WH2-LC3 was made by fusing the WH2 region
of JMY (amino acids 842-982) N-terminal to the LC3 coding sequence of mcherry–
GFP–LC3. All constructs were veriﬁed by sequencing. Rabbit anti-HA Y-11
(sc-805), goat anti-JMY L16 (sc-10027), mouse anti-p53 DO-1 (sc-126) and mouse
anti-p62 (SQSTM1; sc-28359) were from Santa Cruz. Mouse anti-HA antibody
HA11 was from BAbCO. Mouse anti-actin (A1978) and anti-tubulin (T6199)
antibodies were from Sigma. Mouse anti-LC3 (0231-100/LC3-5F10) antibody
was from Nanotools and rabbit anti-LC3B (#2775) and cleaved-PARP (#9541)
antibodies were from Cell Signaling. Mouse anti-JMY antibody has been previously
described42. Primary antibodies for western blotting were used at 1/1,000 with the
exception of actin (1/100,000), tubulin (1/10,000) and JMY (hybridoma
supernatant 1/250 dilution). Uncropped scans are provided in Supplementary
Fig. 8. Primary antibodies for immunoﬂuorescence were used at 1/200 dilution.
HRP-conjugated secondary antibody was from DAKO (1/10,000 dilution). Alexa
Fluor conjugated secondary antibodies and Alexa Fluor 488 conjugated actin were
from Molecular Probes (1/500 dilution). SAHA (Selleckchem) was used at a
concentration of 10mM, rapamycin (Sigma) 1 mM, AZD2014 (Selleckchem) 15 mM,
tubastatin A (ChemieTek) 10 mM and baﬁlomycin A1 (Sigma) 100 nM, unless
noted otherwise. Phalloidin-TRITC was from Sigma. The Arp2/3 inhibitors
CK-666 and CK-869 were from Merck Biosciences.
Cell lines and generation of stable cell lines. HeLa, MCF7, HCT116 p53þ /þ ,
HCT116 p53 / and U2OS cells were grown in 5% FCS-DMEM plus antibiotics
under 5% CO2. HeLa, MCF7 and U2OS cell lines were from Sigma (ECACC) and
paired HCT116 cell lines were a kind gift from B. Vogelstein (Howard Hughes
Medical Institute, The Johns Hopkins University, MD, USA). U2OS cells stably
expressing JMY constructs were obtained after transfection of the appropriate
construct into U2OS cells and carrying out selection with 500 mgml 1 G418.
Transfection. Plasmid transfections were performed using GeneJuice (Merck
Biosciences). siRNA transfections were performed using Oligofectamine
(Invitrogen). In all cell types 25 nM siRNA was used. Human JMY siRNA has
been previously described in ref. 12 (JMY1: 50-gcaacuagaaagcaucaaa-30 ; JMY2:
50-cacucggauugaagaugaa-30 ; JMY3: 50-ccaucacacaguacaacua-30) and control
non-targeting control siRNA #3 was from Dharmacon.
Immunostaining and quantiﬁcation. Cells were seeded onto 13mm glass
coverslips, and ﬁxed with 3.7% formaldehyde followed by ice cold methanol for
10min. Permeabilisation of the cells was performed for 5min with 0.5% Triton
X-100 in phosphate-buffered saline (PBS) followed by incubation with primary
antibody for an hour at room temperature (or overnight). Coverslips were washed
with 0.025% Tween in PBS extensively before adding secondary antibody. Cover-
slips were mounted on microscope slides using Vectashield with or without DAPI
(4,6-diamino-2-phenylindole; to visualize nuclei) as required. Images were
obtained using either an Olympus BX51 inverted ﬂuorescence or Zeiss LSM
780 confocal microscope using a 63 oil-immersion lense. Autophagosome
numbers, mean and total area were calculated using the IN Cell Analyser 1,000
(GE Healthcare). LC3/actin overlap was calculated using Fiji/Image J43.
Immunoprecipitations. For endogenous interactions cells were harvested in TNN
buffer (150mM NaCl, 50mM Tris-HCl pH 7.4, 5mM EDTA, 0.5% NP40 in the
presence of protease inhibitors) after incubating with 10 mM SAHA for 6 h. Lysates
were precleared with protein A/G slurry for 30min at 4 C. Immunoprecipitations
were performed with goat anti-JMY antibody L16 in the presence of protein A/G
slurry overnight at 4 C.
In vitro binding assays. His-tagged JMY was puriﬁed from BL21 cells under
native conditions using Ni-NTA agarose according to the QIAexpressionist
protocol (Qiagen). Approximately 1 mg of His-tagged JMY was incubated with 1 mg
of commercially prepared GST-LC3B (Enzo Life Sciences) or GST control for 1 h in
the presence of TNN buffer before adding glutathione sepharose 4B for 30min
at 4 C. In vitro transcribed and translated proteins were obtained using the
TnT-coupled reticulocyte lysate system (Promega) in the presence of T7
polymerase according to manufacturer’s instructions. TnT (10 ml) lysate was
incubated with 1 mg of GST-LC3B protein in the presence of TNN buffer for 1 h
at 4 C before adding glutathione sepharose 4B for 30min at 4 C to immuno-
precipitate complexes.
G-actin incorporation assay. In situ G-actin incorporation assays were performed
as previously described44 using 0.4 mM Alexa Fluor 488 labelled G-actin. Cells
grown on coverslips were treated for 2min at room temperature before ﬁxation
with 0.4 mM alexa conjugated G-actin together with 1mM ATP in permeabilization
buffer (0.2mgml 1 saponin, 20mM Hepes pH 7.4, 138mM KCl, 4mM MgCl2
and 3mM EGTA). Cells were subsequently ﬁxed and processed for
immunoﬂuorescence as described under immunostaining.
FACS analysis. Cells were seeded into 6 cm dishes and treated as appropriate
before harvesting. Growth media were collected and adherent cells were lifted by
adding 1ml of trypsin per dish. The cells were pelleted (800 g) for 5min at 4 C
and washed once with PBS. The cells were ﬁxed in ice cold 70% ethanol/PBS (v/v).
Fixed cells were washed with PBS and stained in 2% (v/v) propidium iodide in the
presence of 125Uml 1 DNAse-free RNAse A. Stained cells were analysed using
ﬂow cytometry (Accuri C6, BD Bioscience).
MTT assays. MTT assays were performed in 96-well plates using an initial cell
number of 2,000 cells per well and all treatments were performed in triplicate. Cells
were plated in 100 ml of complete medium and allowed to adhere overnight.
The following day the medium was carefully removed and replaced with either
complete medium or EBSS and cells were left for 24 h. MTT activity was measured
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8888
8 NATURE COMMUNICATIONS | 6:7888 | DOI: 10.1038/ncomms8888 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
by treating cells with 10 ml MTT reagent (thiazolyl blue tetrazolium bromide;
5mgml 1 in PBS) per well and incubating at 37 C for 2 h. The medium was
carefully removed and 100 ml dimethylsulfoxide was added to each well and
incubated at room temperature for 10min with agitation. Absorbance was
measured at 570 nm with a reference reading at 650 nm.
RNA isolation, reverse transcription and qPCR. RNA was isolated using the
ReliaPrep miniprep system (Promega) according to manufacturer’s instructions.
RNA (2 mg) was reverse transcribed using MMLV and oligodT primers before
performing real-time PCR using Brilliant III Ultra-Fast SYBR QPCR MM (Agilent
Technologies). GAPDH was used as an internal control and human LC3B primer
sequences were from Scherz-Shouva et al.28. Primer sequences were as follows:
GAPDH F: 50-ttcattgacctcaactacat-30 ; R: 50-gtggcagtgatggcatggac-30 ; LC3B F:
50-accatgccgtcggagaag-30 ; R: 50-atcgttctattatcaccgggatttt-30 . Results were calculated
using 2DDCt.
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